Devidas N. Chaturbhuj

Cornell University — United States

Medicine · Health Sciences

13h-index630citations22works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(18), HIV Research and Treatment(17), HIV/AIDS Research and Interventions(11), SARS-CoV-2 and COVID-19 Research(4), Immunotherapy and Immune Responses(2)

Publications22 total

A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers
Journal of Virology·2025· 1 citedOpen Access
The Evolution of Regulatory Elements in the Emerging Promoter-Variant Strains of HIV-1 Subtype C
Frontiers in Microbiology·2021· 12 citedOpen Access
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
Science Advances·2021· 114 citedOpen Access
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
Pathogens and Immunity·2021· 130 citedOpen Access
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
2021· 30 citedOpen Access
The evolution of regulatory elements in the emerging promoter variant strains of HIV-1
2021· 2 citedOpen Access
Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva
2021· 34 citedOpen Access
HIV-1 pol gene diversity and molecular dating of subtype C from Sri Lanka
PLoS ONE·2020· 2 citedOpen Access
PYRE insertion within HIV-1 subtype C p6-Gag functions as an ALIX-dependent late domain
Scientific Reports·2018· 12 citedOpen Access
HIV drug resistance following a decade of the free antiretroviral therapy programme in India: A review
International Journal of Infectious Diseases·2017· 33 citedOpen Access
Evaluation of 4-thiazolidinone derivatives as potential reverse transcriptase inhibitors against HIV-1 drug resistant strains
Bioorganic Chemistry·2017· 45 cited
Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India
Medicine·2016· 24 citedOpen Access
Outcome of patients on second line antiretroviral therapy under programmatic condition in India
BMC Infectious Diseases·2015· 52 citedOpen Access
Emergence of Drug Resistance in Human Immunodeficiency Virus Type 1 Infected Patients from Pune, India, at the End of 12 Months of First Line Antiretroviral Therapy Initiation
ISRN AIDS·2014· 5 citedOpen Access
Evaluation of a Cost Effective In-House Method for HIV-1 Drug Resistance Genotyping Using Plasma Samples
PLoS ONE·2014· 16 citedOpen Access
Prevalence of Drug Resistance in Human Immunodeficiency Virus Type 1-Infected Treatment-Naive Children in Pune, India
AIDS Research and Human Retroviruses·2014· 9 citedOpen Access
Evaluations of an in-house drug resistance method for HIV-1 drug resistance using ViroSeq™ 2.0 genotyping system as a gold standard
Journal of Virological Methods·2013· 6 cited
Initial Virologic Response and HIV Drug Resistance Among HIV-Infected Individuals Initiating First-line Antiretroviral Therapy at 2 Clinics in Chennai and Mumbai, India
Clinical Infectious Diseases·2012· 34 citedOpen Access
Surveillance of Transmitted HIV Type 1 Drug Resistance Among HIV Type 1-Positive Women Attending an Antenatal Clinic in Kakinada, India
AIDS Research and Human Retroviruses·2011· 19 cited
Genetic Conservation in gp36 Transmembrane Sequences of Indian HIV Type 2 Isolates
AIDS Research and Human Retroviruses·2011· 4 cited
page 1 of 2Next →

Frequent Co-authors

Ramesh Paranjape(14), Srikanth Tripathy(11), Nitin Hingankar(6), Raman Gangakhedkar(6), John P. Moore(5), Rogier W. Sanders(4), Smita Kulkarni(4), Sandhya Kabra(4), Sourav Sen(4), Anila Yasmeen(3), Albert Cupo(3), Per Johan Klasse(3), Swarali Kurle(3), Smita R. Thorat(3), Padmini Srikantiah(3), Sharda R. Datkar(3), Pravin S. Deshmukh(3), D. C. S. Reddy(3), Renu Garg(3), Thomas J. Ketas(2)